

GEOVAX LABS INC. --- ANNOUNCES MERGER CLOSING DATE

Atlanta, Ga., September 22, 2006 -- GeoVax, Inc., a privately held biotechnology company based in Atlanta, Georgia, today announced the closing of the Merger with Dauphin Technology, Inc. has been set for September 29, 2006. "Dauphin" is a publicly traded company based in Schaumburg, Illinois whose common stock trades on the Pink Sheets Electronic Quotation Service under the symbol "DNTK".

On the day of the closing, Dauphin's name will change to GeoVax Labs Inc. and the stock will trade with a new CUSIP number and symbol which will be announced immediately after the closing.

GeoVax AIDS vaccines consisting of DNA and MVA components both expressing key AIDS virus proteins, have entered a 2nd series of 4 additional planned human trials at several sites in the USA. These trials, initiated in April 2006, are being conducted by the HVTN [HIV Vaccine Trials Network], a division of the National Institutes of Health.

A previous human trial evaluating our DNA-AIDS vaccine was satisfactory and recently concluded. Non human primate studies of the GeoVax AIDS vaccines demonstrated protection of 22 of 23 [96%] against the development of AIDS for over 3 ½ years while 5 of 6 non-vaccinated controls developed AIDS within 10 months.

Safe Harbor Statement

All statements in this news release that are not statements of historical fact are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, whether; GeoVax can develop vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be determined to be safe for use in humans, GeoVax's vaccines will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the required capital to complete development of its vaccines, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so.